Previous Article | Next Article 
Journal of Virology, October 2001, p. 9991-9994, Vol. 75, No. 20
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.20.9991-9994.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Novel cis-Acting Replication Element in the
Adeno-Associated Virus Type 2 Genome Is Involved in Amplification
of Integrated rep-cap Sequences
Pascale
Nony,1,
Jacques
Tessier,1
Gilliane
Chadeuf,1
Peter
Ward,2
Aurélie
Giraud,1
Marc
Dugast,1
R. Michael
Linden,2,3
Philippe
Moullier,1 and
Anna
Salvetti1,*
Laboratoire de Thérapie Génique, CHU Hotel
Dieu, 44035 Nantes Cedex 01, France,1 and
Institute for Gene Therapy and Molecular
Medecine2 and Department of
Microbiology,3 Mt. Sinai School of Medicine, New
York, New York 10029
Received 7 May 2001/Accepted 9 July 2001
 |
ABSTRACT |
This study identifies a region of the adeno-associated
virus type 2 (AAV-2) rep gene (nucleotides 190 to 540 of
wild-type AAV-2) as a cis-acting Rep-dependent element able
to promote the replication of transiently transfected plasmids. This
viral element is also shown to be involved in the amplification of
integrated sequences in the presence of adenovirus and Rep proteins.
 |
TEXT |
It was previously reported that
efficient recombinant adeno-associated virus (AAV) production using
stable rep-cap cell lines correlated with a 100-fold
amplification of the AAV-2 genes upon adenovirus infection (3,
9). This phenomenon, which occurred despite the absence of
inverted terminal repeats (ITRs) generated extrachromosomal
double-stranded DNA molecules harboring the rep-cap genes
and required the activity of the adenovirus DNA binding protein,
cellular polymerases, and Rep proteins (9). A question that remained unanswered was whether the rep-cap
amplification was dependent on the activity of an as-yet-unidentified
viral origin of replication present within the viral genome.
To answer this question, we investigated if a
rep-cap-containing plasmid was able to replicate following
transient transfection into adenovirus-infected cells. 293 cells were
transfected with plasmid pRCtag containing the rep-cap
genome with the ITRs deleted, ligated to a 3' tag sequence,
and then mock or adenovirally infected. After DNA extraction,
replication was assessed by digestion with DpnI or
MboI followed by Southern blot analysis using a
tag probe (Fig. 1). Cleavage
by DpnI indicates that both strands are methylated in the
absence of replication of the transfected DNA; cleavage by
MboI occurs only if both strands are unmethylated as a
result of two rounds of replication. In the absence of adenovirus, the pRCtag plasmid did not replicate (Fig. 1B, lanes 5 and 6). In contrast,
upon adenoviral infection, a fraction of the plasmid DNA was
susceptible to MboI digestion (Fig. 1B, lane 9), indicating that some input rep-cap molecules had replicated. After
DpnI digestion, high-molecular-weight resistant bands were
detected as weak signals, suggesting that pRCtag replication generated
products which are heterogenous in size (Fig. 1B, lane 8).

View larger version (50K):
[in this window]
[in a new window]
|
FIG. 1.
In vivo replication analysis of
pRCtag and pRCtag plasmids. (A) Circular map of the pRCtag and
pRCtag plasmids: the tag located at the 3' end of the
rep-cap genes (hatched area) corresponds to a 404-bp
X174-derived sequence. Plasmid pRCtag differs from pRCtag by a
350-bp deletion in the 5' portion of the rep gene (nt 190 to
540 of wild-type AAV-2) that removes the entire p5 promoter and the 5'
portion of the rep open reading frame. The positions of the
two relevant DpnI-MboI sites are indicated. (B)
293 cells were transfected with the pRCtag or the pRCtag plasmid in
the presence (+pRep) or absence ( pRep) of the pRep plasmid, encoding
for the Rep proteins under the control of the AAV-2 p5 and p19
promoters, and subsequently infected (+Ad) or not infected ( Ad) with
adenovirus. (C) pRCtag and pRCtag were similarly transfected into
HeRC32 cells that harbor one integrated copy of the ITR-deleted AAV-2
genome (1). Total genomic DNA was extracted 48 h
later, digested with DpnI (D) or MboI (M), and
analyzed on a Southern blot by using a tag probe. As a
control (lanes 1, 2, and 3), untransfected pRCtag plasmid DNA mixed
with 10 µg of total DNA from 293 cells was digested with
DpnI or MboI and similarly analyzed using the
tag probe. The expected 1,430-bp
DpnI-MboI fragment hybridizing to the
tag probe is indicated.
|
|
To identify the cis element(s) involved in pRCtag
replication, we focused on the 5' portion of the rep gene
which includes a Rep binding site (RBS). (nucleotides [nt] 260 to 284 of wild-type AAV-2) and a trs-like motif (nt 287 of
wild-type AAV-2) (4, 12). The presence of both elements in
the ITRs is known to be essential for wild-type AAV-2 replication
(6, 8). A rep-cap plasmid containing a deletion
in the 5' portion of the rep gene (nt 190 to 540 of
wild-type AAV-2) was generated (pRCtag
) and evaluated as described
above. Because pRCtag
no longer produced the large Rep proteins
(data not shown), its replicative activity was tested with or without a
cotransfected pRep plasmid to provide Rep proteins in trans.
In adenovirus-infected 293 cells, replication of the pRCtag
plasmid
was undetectable and only partially restored in the presence of Rep
proteins (Fig. 1B, lanes 15 and 18). To exclude the possibility that
the low level of pRCtag
replication was due to the inefficient
transfection of plasmid pRep, the same experiment was reproduced using
HeRC32 cells, a stable cell line which expresses the four Rep proteins
upon adenovirus infection (1). Again, plasmid pRCtag
replicated much less efficiently than plasmid pRCtag (Fig. 1C, lanes 21 and 24). Overall, these data suggested that this 350-nt region of the
rep gene behaved as a cis-acting replication
element (CARE). The residual level of pRCtag
replication observed
with 293 and HeRC32 cells could be due either to a recombination event
between the plasmid and the cotransfected or endogenous rep
sequences or to the presence of additional replication element(s) in
the deleted rep-cap genome.
To confirm the role of this viral region in replication, the CARE
element was cloned upstream of the lacZ gene in the same or
opposite orientation and tested as previously described (Fig. 2). Both pCARE.LZ1 and
pCARE.LZ2 plasmids replicated in the presence of Rep
proteins and adenovirus (Fig. 2B, lanes 15 and 18), whereas no
replication products were detected with a pLZ control plasmid (lanes 1 to 3). The ability of CARE to promote replication in a Rep-dependent
manner was further evidenced by two additional experiments. First, a
cell-free DNA replication assay was performed, in which
EcoRI-digested pLZ, pCARE.LZ1 or
pCARE.LZ2 plasmids were incubated with cell extracts from
uninfected HeLa cells with or without purified Rep68 protein (7,
13). Despite a significant level of DNA repair which occurred
with each DNA template, addition of purified Rep68 resulted in a 13- and 8.5-fold increase in the incorporation of labeled nucleotides only
in the upper band containing the CARE sequence, for both plasmids CS pCARE.LZ1 and pCARE.LZ2, respectively (Fig.
3, lanes 4 and 6).
Second, the RBS and the trs-like elements contained in the
p5 region were individually mutated in the pCARE.LZ1
plasmid (Fig. 4A). When tested in a
replication assay, mutation of either the RBS or the trs
element impaired replication of the pCARE.LZ1 plasmid
despite the presence of Rep proteins and adenovirus (Fig. 4B, lanes 9 and 12). The same result was obtained upon transfection in HeRC32 cells
(data not shown).

View larger version (68K):
[in this window]
[in a new window]
|
FIG. 2.
In vivo replication assay of pCARE.LZ plasmids. (A)
Circular map of pCARE.LZ plasmids. The CARE sequence (190 to 540 bp of
wild-type AAV-2), indicated by the hatched area, was introduced
upstream of the CMVLacZ cassette either in the same
(pCARE.LZ1) or opposite (pCARE.LZ2)
orientation. The positions of the relevant
DpnI-MboI sites are indicated. (B) 293 cells were
transfected with the indicated plasmid in the presence or absence of
the pRep plasmid and adenovirus infection. DNA was analyzed as
described in the legend of Fig. 1 by using a lacZ probe. The
expected 552-, 426-, and <100-bp DpnI-MboI
fragments hybridizing to the lacZ probe are indicated.
|
|

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 3.
In vitro replication assay of pCARE.LZ plasmids. (A)
Circular map of the pLZ and pCARE.LZ1/2 plasmids. Two major
linear species are generated upon EcoRI digestion: one of
3,077 bp that is common to both plasmids and corresponds to the
lacZ gene and one of 3,261 and 3,690 bp for pLZ and
pCARE.LZ1/2, respectively, that corresponds to the CARE
sequence associated with the rest of the plasmid. (B) The
EcoRI-digested plasmid DNA was used directly in the in vitro
replication assay, so each reaction mixture contained equimolar amounts
of the two larger DNA fragments. Replication assays were performed as
previously described using a cellular extract from uninfected HeLa
cells, supplemented or not with purified Rep68 protein
(13).
|
|

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 4.
Mutational analysis of CARE element. (A) Sequence of the
wild-type (wt) and mutated CARE element between nt 227 and 294 of
wild-type AAV-2. The mRBS mutation was previously described by Pereira
et al. (5). The mtrs mutation was introduced by changing 6 bp surrounding the trs site described by Wang et al.
(12). The presence of each mutation was verified by
sequencing. (B) 293 cells were transfected with the indicated construct
with or without the pRep plasmid and adenovirus infection. DNA was
analyzed as described in the legend of Fig. 1 by using a
lacZ probe.
|
|
Altogether, these findings established the presence of a Rep-dependent
replication element between nt 190 and 540 of wild-type AAV-2. These
results support and extend the observation made by Tullis and Shenk
(10), who demonstrated the presence of a positive cis-acting element between nt 194 and 1882 of AAV-2.
Furthermore, CARE features resembled those already described for the
chromosome 19 AAVS1 region that also contains an RBS and a
trs element (2, 11, 14).
Finally, we wanted to determine if CARE could also induce the
amplification of an integrated sequence. A stable cell line (HeCARE.LZ)
was obtained by cotransfection of pCARE.LZ1 and the PGK-Neo
plasmids into HeLa cells. Control cells (He.LZ) that integrated a
lacZ sequence without CARE were obtained similarly. The
cells were then tested for the amplification of integrated lacZ sequences. As seen by Southern blot analysis using a
lacZ probe, an increase in the lacZ copy number
was observed in HeCARE.LZ cells upon adenovirus infection and
transfection of plasmid pRep, but not in control He.LZ cells (Fig.
5, lanes 8 and 4). The level of
lacZ gene amplification measured in HeCARE.LZ cells was
likely underestimated due to the low transfection efficiency of HeLa cells (less than 10%). Importantly, neither adenovirus infection alone
nor expression of the rep gene under the control of either the p5 (plasmid pRep) or the cytomegalovirus (CMV) promoter (plasmid pCMVRep) was sufficient to induce lacZ gene amplification in
HeCARE.LZ cells (Fig. 5, lanes 6, 7, and 13). These results indicated
that integration of CARE can lead to the amplification of an
heterologous adjacent sequence and that Rep proteins are necessary
together with adenovirus for this phenomenon to occur. This finding
suggests that the amplification of an integrated rep-cap
genome, which shares this dual requirement (9), is also
CARE dependent. As such, the identification of CARE has important
implications for the design of stable AAV-2-packaging cells.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 5.
Analysis of lacZ amplification in stable
CARE-lacZ HeLa cells. He.LZ or HeCARE.LZ cells, containing
an integrated lacZ or a CARE-lacZ sequence,
respectively, were either transfected with a Rep-expressing plasmid
(+pRep or +pCMVRep), infected with wild-type adenovirus (+Ad), or both.
Total genomic DNA extracted 48 h later was digested with
HincII and analyzed on a Southern blot by using a
lacZ probe. The position of the expected 1.8-kb
lacZ band is indicated. The standard samples with 0.1, 1, and 10 lacZ, copies per cell were obtained by adding 4, 40, and 400 pg of pCARE.LZ plasmid, respectively, to 10 µg of total
genomic DNA from noninfected HeLa cells.
|
|
 |
ACKNOWLEDGMENTS |
Pascale Nony and Jacques Tessier contributed equally to this work.
This work was supported by the Association Française contre les
Myopathies (AFM), Vaincre les Maladies Lysosomales (VML), Association
Nantaise de Thérapie Génique (ANTG), and the Fondation pour
la Thérapie Génique en Pays de la Loire. It was also
supported, in part, by NIH grants DK55609 and DK57746 to R.M.L.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Laboratoire de
Thérapie Génique, CHU Hotel Dieu, Bâtiment Jean
Monnet, 30 avenue Jean Monnet, 44035 Nantes cedex 01, France. Phone:
(33) 240087490. Fax: (33) 240087491. E-mail:
salvetti{at}sante.univ-nantes.fr.
Present address: CNRS-UMR5641, Domaine Rockefeller, 69373 Lyon
Cedex O9, France.
 |
REFERENCES |
| 1.
|
Chadeuf, G.,
D. Fayre,
J. Tessier,
N. Provost,
P. Nony,
J. Kleinschmidt,
P. Moullier, and A. Salvetti.
2000.
Efficient recombinant adeno-associated virus production by a stable rep-cap HeLa cell line correlates with adenovirus-induced amplification of the integrated rep-cap genome.
J. Gene Med.
2:260-268[CrossRef][Medline].
|
| 2.
|
Linden, R. M.,
E. Winocour, and K. I. Berns.
1996.
The recombination signals for adeno-associated virus site-specific integration.
Proc. Natl. Acad. Sci. USA.
93:7966-7972[Abstract/Free Full Text].
|
| 3.
|
Liu, X.,
F. Voulgaropoulou,
R. Chen,
P. R. Johnson, and K. R. Clark.
2000.
Selective rep-cap gene amplificiation as a mechanism for high-titer recombinant AAV production from stable cell lines.
Mol. Ther.
2:394-403[CrossRef][Medline].
|
| 4.
|
McCarty, D. M.,
D. J. Pereira,
I. Zolotukhin,
X. Zhou,
J. H. Ryan, and N. Muzyczka.
1994.
Identification of linear DNA sequences that specifically bind the adeno-associated virus Rep protein.
J. Virol.
68:4988-4997[Abstract/Free Full Text].
|
| 5.
|
Pereira, D. J.,
D. M. McCarty, and N. Muzyczka.
1997.
The adeno-associated virus (AAV) Rep protein acts as both a repressor and an activator to regulate AAV transcription during a productive infection.
J. Virol.
71:1079-1088[Abstract].
|
| 6.
|
Ryan, J. H.,
S. Zolotukhin, and N. Muzyczka.
1996.
Sequence requirements for binding of Rep68 to the adeno-associated virus terminal repeats.
J. Virol.
70:1542-1553[Abstract].
|
| 7.
|
Smith, D. H.,
P. Ward, and R. M. Linden.
1999.
Comparative characterization of Rep proteins from the helper-dependent adeno-associated virus type 2 and the autonomous goose parvovirus.
J. Virol.
73:2930-2937[Abstract/Free Full Text].
|
| 8.
|
Snyder, R. O.,
D. S. Im,
T. Ni,
X. Xiao,
R. J. Samulski, and N. Muzyczka.
1993.
Features of the adeno-associated virus origin involved in substrate recognition by the viral Rep protein.
J. Virol.
67:6096-6104[Abstract/Free Full Text].
|
| 9.
|
Tessier, J.,
G. Chadeuf,
P. Nony,
H. Avet-Loiseau,
P. Moullier, and A. Salvetti.
2001.
Characterization of adenovirus-induced inverted terminal repeat-independent amplification of integrated adeno-associated virus rep-cap sequences.
J. Virol.
75:375-383[Abstract/Free Full Text].
|
| 10.
|
Tullis, G. E., and T. Shenk.
2000.
Efficient replication of adeno-associated virus type 2 vectors: a cis-acting element outside of the terminal repeats and a minimal size.
J. Virol.
74:11511-11521[Abstract/Free Full Text].
|
| 11.
|
Urcelay, E.,
P. Ward,
S. M. Wiener,
B. Safer, and R. M. Kotin.
1995.
Asymmetric replication in vitro from a human sequence element is dependent on adeno-associated virus Rep protein.
J. Virol.
69:2038-2046[Abstract].
|
| 12.
|
Wang, X.-S., and A. Srivastava.
1997.
A novel terminal resolution-like site in the adeno-associated virus type 2 genome.
J. Virol.
71:1140-1146[Abstract].
|
| 13.
|
Ward, P.,
F. B. Dean,
M. E. O'Donnell, and K. I. Berns.
1998.
Role of the adenovirus DNA-binding protein in in vitro adeno-associated virus DNA replication.
J. Virol.
72:420-427[Abstract/Free Full Text].
|
| 14.
|
Weitzman, M. D.,
S. R. Kyostio,
R. M. Kotin, and R. A. Owens.
1994.
Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA.
Proc. Natl. Acad. Sci. USA.
91:5808-5812[Abstract/Free Full Text].
|
Journal of Virology, October 2001, p. 9991-9994, Vol. 75, No. 20
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.20.9991-9994.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Aslanidi, G., Lamb, K., Zolotukhin, S.
(2009). An inducible system for highly efficient production of recombinant adeno-associated virus (rAAV) vectors in insect Sf9 cells. Proc. Natl. Acad. Sci. USA
106: 5059-5064
[Abstract]
[Full Text]
-
Nash, K., Chen, W., Salganik, M., Muzyczka, N.
(2009). Identification of Cellular Proteins That Interact with the Adeno-Associated Virus Rep Protein. J. Virol.
83: 454-469
[Abstract]
[Full Text]
-
Fragkos, M., Breuleux, M., Clement, N., Beard, P.
(2008). Recombinant Adeno-Associated Viral Vectors Are Deficient in Provoking a DNA Damage Response. J. Virol.
82: 7379-7387
[Abstract]
[Full Text]
-
Guilbaud, M., Chadeuf, G., Avolio, F., Francois, A., Moullier, P., Recchia, A., Salvetti, A.
(2008). Relative Influence of the Adeno-Associated Virus (AAV) Type 2 p5 Element for Recombinant AAV Vector Site-Specific Integration. J. Virol.
82: 2590-2593
[Abstract]
[Full Text]
-
Cotmore, S. F., Gottlieb, R. L., Tattersall, P.
(2007). Replication Initiator Protein NS1 of the Parvovirus Minute Virus of Mice Binds to Modular Divergent Sites Distributed throughout Duplex Viral DNA. J. Virol.
81: 13015-13027
[Abstract]
[Full Text]
-
Ward, P., Clement, N., Linden, R. M.
(2007). cis Effects in Adeno-Associated Virus Type 2 Replication. J. Virol.
81: 9976-9989
[Abstract]
[Full Text]
-
Murphy, M., Gomos-Klein, J., Stankic, M., Falck-Pedersen, E.
(2007). Adeno-Associated Virus Type 2 p5 Promoter: a Rep-Regulated DNA Switch Element Functioning in Transcription, Replication, and Site-Specific Integration. J. Virol.
81: 3721-3730
[Abstract]
[Full Text]
-
Glauser, D. L., Saydam, O., Balsiger, N. A., Heid, I., Linden, R. M., Ackermann, M., Fraefel, C.
(2005). Four-Dimensional Visualization of the Simultaneous Activity of Alternative Adeno-Associated Virus Replication Origins. J. Virol.
79: 12218-12230
[Abstract]
[Full Text]
-
Francois, A., Guilbaud, M., Awedikian, R., Chadeuf, G., Moullier, P., Salvetti, A.
(2005). The Cellular TATA Binding Protein Is Required for Rep-Dependent Replication of a Minimal Adeno-Associated Virus Type 2 p5 Element. J. Virol.
79: 11082-11094
[Abstract]
[Full Text]
-
Nony, P., Chadeuf, G., Tessier, J., Moullier, P., Salvetti, A.
(2002). Evidence for Packaging of rep-cap Sequences into Adeno-Associated Virus (AAV) Type 2 Capsids in the Absence of Inverted Terminal Repeats: a Model for Generation of rep-Positive AAV Particles. J. Virol.
77: 776-781
[Abstract]
[Full Text]
-
Musatov, S., Roberts, J., Pfaff, D., Kaplitt, M.
(2002). A cis-Acting Element That Directs Circular Adeno-Associated Virus Replication and Packaging. J. Virol.
76: 12792-12802
[Abstract]
[Full Text]
-
Qiao, C., Wang, B., Zhu, X., Li, J., Xiao, X.
(2002). A Novel Gene Expression Control System and Its Use in Stable, High-Titer 293 Cell-Based Adeno-Associated Virus Packaging Cell Lines. J. Virol.
76: 13015-13027
[Abstract]
[Full Text]
-
Philpott, N. J., Giraud-Wali, C., Dupuis, C., Gomos, J., Hamilton, H., Berns, K. I., Falck-Pedersen, E.
(2002). Efficient Integration of Recombinant Adeno-Associated Virus DNA Vectors Requires a p5-rep Sequence in cis. J. Virol.
76: 5411-5421
[Abstract]
[Full Text]